Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
Sri Harsha Tella,1 Amit Mahipal,2 Anuhya Kommalapati,3 Zhaohui Jin2 1Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC, USA; 2Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; 3Department of Hematology and Medical Oncology, H. Lee Moffitt C...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-11-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/evaluating-the-safety-and-efficacy-of-nivolumab-in-patients-with-advan-peer-reviewed-article-OTT |
id |
doaj-a49c9192547f4d3f89a2da776190518c |
---|---|
record_format |
Article |
spelling |
doaj-a49c9192547f4d3f89a2da776190518c2020-11-24T21:56:57ZengDove Medical PressOncoTargets and Therapy1178-69302019-11-01Volume 12103351034250044Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to DateTella SHMahipal AKommalapati AJin ZSri Harsha Tella,1 Amit Mahipal,2 Anuhya Kommalapati,3 Zhaohui Jin2 1Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC, USA; 2Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; 3Department of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USACorrespondence: Zhaohui JinDepartment of Medical Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USATel +1507-293-0487Fax +1507-284-1803Email Jin.Zhaohui@mayo.eduAbstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a dismal prognosis, especially when diagnosed at advanced stages. Surgical resection of the primary lesion, liver-directed therapies, and orthotropic liver transplantation are employed in localized disease depending upon the clinical status, underlying liver function, the size, and location of the liver lesions. Systemic therapy plays a critical role in the management of advanced HCC. Sorafenib had remained as the only United States Food and Drug Administration (US-FDA)-approved systemic therapeutic agent for approximately a decade since its approval in 2007, until the advent of immunotherapy and a better understanding of HCC molecular pathogenesis changed the landscape of advanced HCC management. Lenvatinib was approved as an alternative first-line agent, whereas regorafenib, nivolumab, pembrolizumab, ramucirumab, and cabozantinib were approved as second-line agents for HCC patients who could not tolerate or whose disease progressed on sorafenib. Nivolumab and pembrolizumab are the two immunotherapeutic agents that were conditionally approved by the US-FDA based on the encouraging results in Phase I/II trials. This review discusses the potential role of immunotherapy in advanced HCC with a special focus on nivolumab.Keywords: liver cancer, immunotherapy, nivolumab, lenvatinib, sorafenibhttps://www.dovepress.com/evaluating-the-safety-and-efficacy-of-nivolumab-in-patients-with-advan-peer-reviewed-article-OTTliver cancerimmunotherapynivolumablenvatinibsorafenib |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tella SH Mahipal A Kommalapati A Jin Z |
spellingShingle |
Tella SH Mahipal A Kommalapati A Jin Z Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date OncoTargets and Therapy liver cancer immunotherapy nivolumab lenvatinib sorafenib |
author_facet |
Tella SH Mahipal A Kommalapati A Jin Z |
author_sort |
Tella SH |
title |
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date |
title_short |
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date |
title_full |
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date |
title_fullStr |
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date |
title_full_unstemmed |
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date |
title_sort |
evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2019-11-01 |
description |
Sri Harsha Tella,1 Amit Mahipal,2 Anuhya Kommalapati,3 Zhaohui Jin2 1Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC, USA; 2Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; 3Department of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USACorrespondence: Zhaohui JinDepartment of Medical Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USATel +1507-293-0487Fax +1507-284-1803Email Jin.Zhaohui@mayo.eduAbstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a dismal prognosis, especially when diagnosed at advanced stages. Surgical resection of the primary lesion, liver-directed therapies, and orthotropic liver transplantation are employed in localized disease depending upon the clinical status, underlying liver function, the size, and location of the liver lesions. Systemic therapy plays a critical role in the management of advanced HCC. Sorafenib had remained as the only United States Food and Drug Administration (US-FDA)-approved systemic therapeutic agent for approximately a decade since its approval in 2007, until the advent of immunotherapy and a better understanding of HCC molecular pathogenesis changed the landscape of advanced HCC management. Lenvatinib was approved as an alternative first-line agent, whereas regorafenib, nivolumab, pembrolizumab, ramucirumab, and cabozantinib were approved as second-line agents for HCC patients who could not tolerate or whose disease progressed on sorafenib. Nivolumab and pembrolizumab are the two immunotherapeutic agents that were conditionally approved by the US-FDA based on the encouraging results in Phase I/II trials. This review discusses the potential role of immunotherapy in advanced HCC with a special focus on nivolumab.Keywords: liver cancer, immunotherapy, nivolumab, lenvatinib, sorafenib |
topic |
liver cancer immunotherapy nivolumab lenvatinib sorafenib |
url |
https://www.dovepress.com/evaluating-the-safety-and-efficacy-of-nivolumab-in-patients-with-advan-peer-reviewed-article-OTT |
work_keys_str_mv |
AT tellash evaluatingthesafetyandefficacyofnivolumabinpatientswithadvancedhepatocellularcarcinomaevidencetodate AT mahipala evaluatingthesafetyandefficacyofnivolumabinpatientswithadvancedhepatocellularcarcinomaevidencetodate AT kommalapatia evaluatingthesafetyandefficacyofnivolumabinpatientswithadvancedhepatocellularcarcinomaevidencetodate AT jinz evaluatingthesafetyandefficacyofnivolumabinpatientswithadvancedhepatocellularcarcinomaevidencetodate |
_version_ |
1725856177371217920 |